The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.
Study Type
OBSERVATIONAL
Enrollment
249
As prescribed by treating physicians
As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
Unnamed facility
Granada, Spain
Time in therapeutic range (TTR) values in the last 6 months
Time frame: 6 months
Presence of stroke
Presence of stroke prior and subsequent to treatment
Time frame: 12 months
Active substance received
Rivaroxaban or VKAs (Acenocoumarol and Warfarin)
Time frame: 12 months
Date of stroke
Time frame: 12 months
Type of stroke
Type of stroke acccording to patients group: unknown, haemorrhagic or ischaemic.
Time frame: 12 months
Duration of treatment (in days)
Time frame: 12 months
Dose of the prescribed treatment
Time frame: 12 months
Frequency of the prescribed treatment (in hours)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.